These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33538211)

  • 1. Targeting
    Robinson H; Green M; Radkar G; Ready N; Strickler J
    Cancer Invest; 2021 Mar; 39(3):235-239. PubMed ID: 33538211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
    Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
    Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sinonasal undifferentiated carcinoma (SNUC): morphoproteomic-guided treatment paradigm with clinical efficacy.
    Ansari M; Guo S; Fakhri S; Citardi MJ; Blanco A; Patino M; Buryanek J; Amato R; Karni R; Brown RE
    Ann Clin Lab Sci; 2013; 43(1):45-53. PubMed ID: 23462605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature.
    Zielinski V; Laban S; Tribius S; Schafhausen P; Veldhoen S; Knecht R; Clauditz T; Muenscher A
    Ear Nose Throat J; 2016 Jan; 95(1):23-8. PubMed ID: 26829682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
    Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F
    Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
    Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
    Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.
    Rochigneux P; Thomassin-Piana J; Laibe S; Brunelle S; Salem N; Escudier B; Vassal G; Gravis G
    BMC Cancer; 2018 Nov; 18(1):1159. PubMed ID: 30466410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
    Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
    J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of sinonasal undifferentiated carcinoma.
    Gelbard A; Hale KS; Takahashi Y; Davies M; Kupferman ME; El-Naggar AK; Myers JN; Hanna EY
    Head Neck; 2014 Jan; 36(1):15-21. PubMed ID: 23633104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
    Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
    Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
    Riedel R; Michels S; Heydt C; Siemanowski J; Kobe C; Bunck A; Schäfer S; Fischer RN; Scheffler M; Abdulla DSY; Nogová L; Koleczko S; Merkelbach-Bruse S; Büttner R; Wolf J
    Lung Cancer; 2019 Jul; 133():20-22. PubMed ID: 31200822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of markers predictive for response to induction chemotherapy in patients with sinonasal undifferentiated carcinoma.
    Takahashi Y; Gleber-Netto FO; Bell D; Roberts D; Xie TX; Abdelmeguid AS; Pickering C; Myers JN; Hanna EY
    Oral Oncol; 2019 Oct; 97():56-61. PubMed ID: 31421472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors.
    Li JW; Cao SH; Xu JL; Zhong H
    Cancer Biol Ther; 2019; 20(9):1183-1186. PubMed ID: 31131689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sinonasal Undifferentiated Carcinoma.
    Abdelmeguid AS; Bell D; Hanna EY
    Curr Oncol Rep; 2019 Feb; 21(3):26. PubMed ID: 30806835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
    Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
    Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.
    Xu Y; Fan Y
    Cancer Biol Ther; 2019; 20(2):145-149. PubMed ID: 30422759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
    Plenker D; Bertrand M; de Langen AJ; Riedel R; Lorenz C; Scheel AH; Müller J; Brägelmann J; Daßler-Plenker J; Kobe C; Persigehl T; Kluge A; Wurdinger T; Schellen P; Hartmann G; Zacherle T; Menon R; Thunnissen E; Büttner R; Griesinger F; Wolf J; Heukamp L; Sos ML; Heuckmann JM
    Clin Cancer Res; 2018 Mar; 24(6):1337-1343. PubMed ID: 29284707
    [No Abstract]   [Full Text] [Related]  

  • 20. Morphoproteomics and Biomedical Analytics Identify the c-Myc, EZH2, Sirt1 and CXCR4 Pathways as Potential Blocks to Differentiation Leading to Proliferation and Metastatic Potential in Sinonasal Undifferentiated Carcinoma (SNUC) and Provide Therapeutic Options: A Case Study.
    Brown RE; Roy S; McGuire MF
    Ann Clin Lab Sci; 2018 Sep; 48(5):659-664. PubMed ID: 30373873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.